ArticleBMC microbiology2025
Computational guided identification of novel anti-mycobacterial agent proved by in-vitro and in-vivo validation.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn upsurge of antibiotic resistant bacteria such as Mycobacterium tuberculosis is recorded on daily bases as a result of many factors including: the daily antibiotics exploitation, failure to follow lengthy complex drug regimen, and ongoing bacterial mutation. TB treatment protocol is usually a lengthy and expensive one that is composed of 4 or even 5 drugs that have multiple substantial side effects. Traditional drug discovery methodologies are usually lengthy multifaceted process complicated with unpredictable outcomes in terms of efficacy and safety, hence there is an urge to find innovative drug discovery method that can produce multiple novel potential antimycobacterial agents that are safe and effective both in-vitro and in-vivo.
resultsThe obtained results illustrated that maleic acid represented a potential drug with minimum inhibitory concentration of 312 µg/ml and an identical minimum bactericidal concentration against Mycobacterium tuberculosis. Its IC50 was measured to be 374.44 mg/ml with SI of 1200. Preliminary testing showed that maleic acid can be considered as a possible histidinol-phosphate aminotransferase inhibitor with a high binding affinity (-5.0475 kcal/mol) and promising molecular dynamics. Maleic acid combination with rifampicin had ƩFIC of 0.375 which indicated synergistic activity between them. It efficiently produced 3 ± 0.3009 log
conclusionAfter careful filtration processes, computational guided scavenge of online protein databases for potential druggable targets represents a promising pathway for identification of novel antimycobacterial agents. One of the promising identified agents was maleic acid which can act as an alternative/additional drug for combating tuberculosis infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.